Barclays Maintains an 'Overweight' on Merck (MRK) - Model Update

Barclays maintains an 'Overweight' on Merck (NYSE: MRK), PT $41.

Barclays analyst says, "We are updating our MRK model to reflect updates to pipeline catalysts as well as an anticipated 3Q 2011 launch of Victrelis. Our FY11 EPS estimates remain unchanged."

"Our 2011 and 2012 revenue estimates are $47,387m (+3% YoY) and $47,680m (+0.6% YoY), respectively. We forecast 2011 and 2012 EPS to be $3.74 (+9%) and $3.86 (+3%), respectively. MRK management guided revenue growth in the low-mid single digits for 2011 and a non-GAAP EPS of $3.66-$3.76."

For more ratings news on Merck click here and for the rating history of Merck click here.

Shares of Merck closed at $36.90 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$231 at Bernstein SocGen
• McGraw Hill (MH) PT Lowered to $14 at UBS on Softer 2027 Outlook
• Marvell (MRVL) PT Raised to $345 at B.Riley, bullish on new CEO